批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2005/06/15 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2025/03/31 |
SUPPL-56(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2020/06/23 |
SUPPL-49(补充) |
Approval |
Labeling-Package Insert,Labeling-Package Insert |
STANDARD
|
|
|
| 2020/01/16 |
SUPPL-48(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2018/04/16 |
SUPPL-45(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/06/29 |
SUPPL-42(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
| 2016/05/31 |
SUPPL-39(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/01/19 |
SUPPL-43(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2014/01/09 |
SUPPL-36(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2013/09/26 |
SUPPL-31(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/09/26 |
SUPPL-26(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2013/05/23 |
SUPPL-37(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2010/07/16 |
SUPPL-27(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2010/07/16 |
SUPPL-25(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2010/07/16 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2009/06/26 |
SUPPL-22(补充) |
Approval |
Labeling-Package Insert,Labeling-Container/Carton Labels |
N/A
|
|
|
| 2009/03/20 |
SUPPL-18(补充) |
Approval |
Efficacy-New Indication |
UNKNOWN
|
|
|
| 2009/03/20 |
SUPPL-17(补充) |
Approval |
Efficacy-New Indication |
UNKNOWN
|
|
|
| 2009/03/20 |
SUPPL-13(补充) |
Approval |
Efficacy-New Indication |
UNKNOWN
|
|
|
| 2009/02/10 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2009/01/29 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2009/01/29 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2009/01/29 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2007/05/18 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2007/04/03 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2007/01/24 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2006/07/12 |
SUPPL-4(补充) |
Approval |
Labeling-Container/Carton Labels,Labeling-Package Insert |
N/A
|
|
|
| 2006/07/12 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:TIGECYCLINE; 剂型/给药途径:POWDER;INTRAVENOUS; 规格:50MG/VIAL; 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021821 |
001 |
NDA |
TYGACIL |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
Yes |
Yes |
AP |
2005/06/15
|
PF PRISM CV |
| 091620 |
001 |
ANDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
No |
No |
AP |
2015/05/27
|
SANDOZ |
| 205645 |
001 |
NDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
Yes |
Yes |
AP |
2016/12/01
|
FRESENIUS KABI USA |
| 211158 |
001 |
NDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
No |
No |
AP |
2018/08/02
|
AMNEAL |
| 204439 |
001 |
ANDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
No |
No |
AP |
2018/12/21
|
APOTEX |
| 206335 |
001 |
ANDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
No |
No |
AP |
2019/06/11
|
EUGIA PHARMA |
| 205722 |
001 |
ANDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Discontinued |
No |
No |
AP |
2019/10/18
|
XELLIA PHARMS APS |
| 214020 |
001 |
ANDA |
TIGECYCLINE |
TIGECYCLINE |
POWDER;INTRAVENOUS |
50MG/VIAL |
Prescription |
No |
No |
AP |
2021/05/13
|
MEITHEAL |